GlaxoSmithKline requests emergency authorization from FDA for Covid antibody drug

Business

In this article

In this photo illustration the British multinational pharmaceutical company GlaxoSmithKline (GSK) logo seen displayed on a smartphone with a computer model of the COVID-19 coronavirus on the background.
Budrul Chukrut | SOPA Images | Getty Images

GlaxoSmithKline and Vir Biotechnology on Friday applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug.

The FDA submission is based on an interim analysis of a phase three trial, which evaluated the drug for the early treatment of Covid-19 in adults at high risk of hospitalization. The drug reduced hospitalizations or death from Covid-19 by 85% compared with a placebo.

The two companies in August started testing the antibody on early-stage Covid-19 patients, hoping to keep symptoms from progressing.

This is a developing story. Please check back for updates.

-Reuters contributed to this report.

Articles You May Like

Mortgage demand falls again even as rates sink further
Kroger hikes forecast after stronger grocery sales top estimates
Stocks making the biggest moves premarket: Marvell Technology, Horizon Therapeutics, DoorDash and more
‘It’s possible the market can rally’: Financial advisors say a recession isn’t inevitable
An uphill battle could await activist Trian as the firm snaps up a stake in Disney